Sign in / Join Now
ETFs & Funds
: A company with such pipeline that has trials in advanced stage should have at 500M+ market cap. impressive results of RA phase 2b.
Somebody knows about $
management? maybe they are not good enough!
Add a reply...
Latest StockTalks »
people get CANF breaking news and analysis by email alert.
Get email alerts on CANF »
Can-Fite Biopharma Ltd
Get latest price
From other sites
Can-Fite BioPharma Announces $5 Million Registered Direct Offering
at TheStreet (Thu, 7:29AM)
Can-Fite Receives IRB Approval To Commence Patient Enrollment In Phase II NAFLD/NASH Trial In Q1 2017
at TheStreet (Jan 9, 2017)
Can-Fite Receives $500,000 Payment As Part Of $3 Million Distribution Deal For Liver Cancer Drug Namodenoson (CF102) In South Korea
at TheStreet (Dec 21, 2016)
New Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy In Treatment Of NASH
at TheStreet (Dec 16, 2016)
American Medical Association's USAN & World Health Organization's INN Approve "Namodenoson" As Generic Name For Can-Fite's Liver Drug CF102
at TheStreet (Nov 16, 2016)